Adaptive Biotechnologies sells clonoSEQ, an FDA-cleared test that measures residual cancer in blood cancers, and runs an Immune Medicine research business it plans to separate.
Adaptive's case rests on clonoSEQ, its FDA-cleared test for residual disease in blood cancers. Second-quarter MRD revenue rose 33% to $66.2 million, test volume rose 43%, and Adaptive raised its 2026 MRD revenue guidance to $268 to $278 million. Updated NCCN myeloma guidelines name clonoSEQ. Adaptive intends to choose a way to separate MRD from Immune Medicine by year-end 2026. In June it sold $345 million of zero-coupon convertible notes and repaid its OrbiMed royalty agreement.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: A separation plan that preserves MRD value
Does Adaptive choose a separation that leaves MRD with its growth and a manageable share of debt?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
clonoSEQ revenue grew 33%; Adaptive picks a path to separate its businesses by year-end
Adaptive's plan to separate MRD and Immune Medicine tests whether a profitable diagnostics business is worth more on its own
clonoSEQ's path to cash-flow breakeven hinges on sustaining MRD volume growth and converting pharma partnerships into recurring milestone revenue
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
vs. direct competitors
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.